Queen's Birthday Honour for Professor Georgina Long
8 June 2020
Congratulations to Melanoma Institute Australia Co-Medical Director, Professor Georgina Long, who has been recognised in the 2020 Queen’s Birthday Honours List announced today by the Governor-General.
Professor Long has been appointed as an Officer (AO) of the Order of Australia (General Division) for distinguished service to medicine, particularly, to melanoma clinical and translational research, and to professional medical societies.
‘This is well deserved recognition of Professor Long’s lifesaving work and ground-breaking research,’ said fellow MIA Co-Medical Director, Professor Richard Scolyer. ‘She has changed the face of melanoma treatment around the world and many thousands of people are alive today thanks to her intellect, determination and passion.
‘It is due to her research and thought leadership globally that the world is now realistically looking towards a day with zero deaths from melanoma,’ he added.
Professor Long is one of the world’s most renowned melanoma clinicians and researchers with her clinical trials tripling life expectancy for some advanced melanoma patients and essentially curing others.
She leads the clinical trials team at MIA, with a focus on targeted therapy and immune-oncology in melanoma, and is Principal Investigator on Phase I, II and III trials in adjuvant and metastatic melanoma, including trials in patients with active brain metastases.
Professor Long is a fierce advocate that recent advances and breakthroughs in melanoma treatment stem from the collective effort of the dedicated multi-disciplinary team at MIA that she co-leads with her colleague and friend Professor Scolyer.
In a double world first, she is the first woman and the first Australian to be President of the prestigious US-based Society for Melanoma Research (SMR). She has authored over 300 publications in melanoma clinical and translational research, including in the world’s leading scientific high-impact journals such as the New England Journal of Medicine and The Lancet, and has presented at hundreds of international conferences.
Professor Long’s Queen’s Birthday Honour follows numerous awards including being named the 2018 Outstanding Researcher of the Year at the NSW Premiers Awards for Outstanding Cancer Research and receiving the prestigious Research Australia, GSK Research Excellence Award in 2018 and the Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research in 2016.
‘Professor Long’s recognition in the Queen’s Birthday Honours List is a proud day for all of us here at Melanoma Institute Australia,’ said CEO Matthew Browne.
‘Not only is she saving lives and changing the future for melanoma patients around the world, but she is also an inspiring role model for all young Australians, particularly women, who may be working towards a career in science and medicine,’ he said.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.
Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.
Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.
MIA recently demonstrated that reflectance confocal microscopy is a useful tool in the clinic to diagnose suspicious-looking lesions in the mouth.
New research is likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost.
Researchers from MIA will present their latest research findings to the world’s largest oncology conference in early June.
Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours
Australian researchers are the first to demonstrate that patients with advanced melanoma which has spread to the brain can have increased life expectancy and possibly even beat the disease.
Melanoma March 2017 - that's a wrap! Thank you to everyone that helped make it happen.
Thank you so much to all those who contributed in a variety of ways to Melanoma March 2017 in 17 different locations and more around the country! You have contributed to getting the Big Data for Melanoma national Research Project happening!
By looking at the ‘dark matter’ of the genome, new research has found that genetic changes in acral and mucosal melanoma are completely different to mutations found in skin melanoma.
‘Slip, slop, slap’ is synonymous with being Australian and playing it safe in the sun. These sun smart rules reduce our chances of getting melanoma of the skin. However, new research tells a different story for those affected by rarer forms of melanoma.
Using MIA's patient database, researchers have developed conditional survival estimates for Stage III melanoma patients to more accurately predict survival outcomes.